2020
Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes
DuBose SN, Li Z, Sherr JL, Beck RW, Tamborlane WV, Shah VN. Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. Journal Of Diabetes Science And Technology 2020, 15: 593-599. PMID: 32064911, PMCID: PMC8120054, DOI: 10.1177/1932296820905904.Peer-Reviewed Original ResearchConceptsEffects of exerciseSensor glucose levelsHealthy individualsResistance exerciseNadir glucoseGlucose levelsNonobese body mass indexT1D Exchange Clinic NetworkPeak postprandial glucoseBody mass indexGlucose concentrationTime of mealsNadir glucose concentrationsConsumption of alcoholMass indexPostprandial glucoseNonexercise dayAerobic exerciseExercise dayClinic networkMean changeFuture therapiesDiabetesDexcom G6Glucose monitor data
2019
Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics
Bitton G, Rom V, Hadelsberg U, Raz I, Cengiz E, Weinzimer S, Tamborlane WV. Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. Journal Of Diabetes Science And Technology 2019, 13: 1123-1128. PMID: 31067999, PMCID: PMC6835184, DOI: 10.1177/1932296819842151.Peer-Reviewed Original ResearchConceptsInjection siteGlucose levelsSerum glucoseSubcutaneous depotMultiple daily insulin injectionsOvernight glucose levelsDaily insulin injectionsBlood glucose controlType 1 diabetesSensor glucose levelsInsulin infusion rateDL increaseInsulin glargineSerum insulinGlucose controlMDI therapyInsulin injectionsInsulin concentrationsPharmacodynamic studiesInfusion rateSkin warmingSeparate daysControl dayRate of absorptionRandom orderLiraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T. Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal Of Medicine 2019, 381: 637-646. PMID: 31034184, DOI: 10.1056/nejmoa1903822.Peer-Reviewed Original ResearchConceptsGlycated hemoglobin levelsType 2 diabetesGastrointestinal adverse eventsAdverse eventsPlasma glucose levelsHemoglobin levelsEnd pointGlycemic controlGlucose levelsMean glycated hemoglobin levelOpen-label extension periodPrimary efficacy end pointDose of liraglutideDouble-blind periodEfficacy end pointPrimary end pointSecondary end pointsBody mass indexNumber of patientsYears of ageMetformin monotherapySubcutaneous liraglutidePlacebo groupLiraglutide groupInclusion criteriaContinuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study
Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Vendrame F, Bergenstal R, Tamborlane WV, Watson SE, Sherr J. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 4356-4364. PMID: 31127824, PMCID: PMC7296129, DOI: 10.1210/jc.2018-02763.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringMedian timeAge groupsProspective studyNondiabetic individualsGlucose levelsAverage glucoseNonobese body mass indexT1D Exchange Clinic NetworkContinuous glucose monitoring (CGM) profilesInsulin-requiring patientsMulticenter prospective studyBody mass indexDifferent age groupsNondiabetic childrenNondiabetic populationGlycemic profileMass indexNondiabetic participantsGlycemic variabilityMean glucoseClinic networkCGM metricsGlycemic metricsGlucose monitoringInternational Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care 2019, 42: 1147-1154. PMID: 30728224, PMCID: PMC6973545, DOI: 10.2337/dc18-2316.Peer-Reviewed Original ResearchConceptsType 1 diabetesSodium-glucose cotransporter inhibitorsDiabetic ketoacidosisCotransporter inhibitorsSGLT inhibitorsNear-normal blood glucose levelsOral antidiabetes medicationsBlood glucose levelsAntidiabetes medicationsInhibitor useBlood pressureAbsolute riskMild hyperglycemiaDKA riskGlycemic variabilityConsensus reportGlucose levelsBody weightDrug AdministrationDiabetesType 1U.S. FoodMedical communityKetoacidosisInternational consensusReversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes
Tamborlane WV, Polidori D, Argenti D, Di Prospero NA. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 649-655. PMID: 29271103, DOI: 10.1111/pedi.12626.Peer-Reviewed Original ResearchConceptsUrinary glucose excretionCanagliflozin 100Type 2 diabetesCanagliflozin 300T2D patientsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPharmacodynamics of canagliflozinSingle daily doseCotransporter 2 inhibitorsTreatment of adultsBody mass indexMaximum plasma concentrationPlasma glucose levelsDose-dependent increasePlasma concentration curveDaily doseGlucose excretionPediatric patientsMass indexPlasma concentrationsRenal thresholdGlucose levelsBody weightPatientsPostprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry
Peters A, Van Name MA, Thorsted B, Piltoft JS, Tamborlane WV. Postprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry. Endocrine Practice 2017, 23: 1201-1209. PMID: 28704103, DOI: 10.4158/ep171813.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolCross-Sectional StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Dosage CalculationsFemaleHumansHypoglycemiaInfantInsulinInsulin Infusion SystemsMaleMiddle AgedPostprandial PeriodRegistriesYoung AdultConceptsRapid-acting insulin analoguesLarger insulin doseT1D Exchange RegistryType 1 diabetesCross-sectional studyDiabetic ketoacidosisInsulin doseGreater prevalenceCurrent rapid-acting insulin analoguesInsulin analoguesSelf-monitoring blood glucosePercent of patientsCharacteristics of patientsPoor glycemic controlExclusion of patientsBody mass indexContinuous glucose monitoringPostprandial dosingGlycemic controlSevere hypoglycemiaBolus insulinMass indexEnrollment questionnaireBlood glucoseGlucose levels
2015
Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes
Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, Wilson DM, Tansey MJ, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL. Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes 2015, 65: 476-485. PMID: 26512024, PMCID: PMC4747456, DOI: 10.2337/db15-1242.Peer-Reviewed Original ResearchConceptsEarly-onset type 1 diabetesType 1 diabetesBlood glucose levelsWhite matter volumeGlucose levelsMatter volumeTime pointsBrain volumeAge-matched control subjectsCortical gray matter volumeMeasures of hyperglycemiaMean HbA1c levelCurrent treatment guidelinesManagement of diabetesRapid brain maturationGray matter volumeTime of scanCortical surface areaHbA1c levelsTreatment guidelinesControl subjectsGlycemic variationsLongitudinal time pointsBrain maturationDiabetesCombining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas
Ang KH, Tamborlane WV, Weinzimer SA. Combining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas. Expert Opinion On Drug Delivery 2015, 12: 1579-1582. PMID: 26389567, PMCID: PMC4837694, DOI: 10.1517/17425247.2015.1074174.Peer-Reviewed Original ResearchConceptsBurden of careGlucose monitoringInsulin deliveryMultiple hormone systemsOverall glucose levelsType 1 diabetesContinuous glucose monitoringGlycemic targetsSevere hypoglycemiaDiabetes controlInsulin delivery systemsInpatient settingGlucose levelsPharmacokinetic profileOutpatient environmentInsulin analoguesPump suspensionInsulin pumpHypoglycemiaPsychosocial tollHormone systemTarget rangeArtificial pancreasPreliminary findingsCareCGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes
Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia 2015, 58: 1167-1174. PMID: 25773405, PMCID: PMC4416994, DOI: 10.1007/s00125-015-3559-y.Peer-Reviewed Original ResearchConceptsC-peptide levelsType 1 diabetesHigher C-peptide levelsC-peptideGlucose levelsTime pointsGlucose valuesMixed meal tolerance testAims/hypothesisThe aimCGM glucose levelsC-peptide responseWeeks of diagnosisOnset of diabetesLower glucose variabilityConclusions/interpretationInMethodsA secondary analysisSensor glucose levelsCGM glucose valuesAdditional time pointsHypothesisThe aimGlucose variabilityTolerance testContinuous glucose monitoring dataInsulin secretionCGM metrics
2014
Persistently high glucose levels in young children with type 1 diabetes
Tansey M, Beck R, Ruedy K, Tamborlane W, Cheng P, Kollman C, Fox L, Weinzimer S, Mauras N, White N, Tsalikian E, Network F. Persistently high glucose levels in young children with type 1 diabetes. Pediatric Diabetes 2014, 17: 93-100. PMID: 25496062, PMCID: PMC4465416, DOI: 10.1111/pedi.12248.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose levelsMin/dContinuous glucose monitorGlycemic excursionsYoung childrenPostprandial glycemic excursionsSuboptimal glycemic controlPercent of participantsHigh glucose levelsOverall mean glucoseMean hemoglobinGlycemic targetsGlycemic controlMedian timeMean glucoseCGM metricsNormal rangeAge groupsT1DHyperglycemic rangeValue 71Age rangeCGM dataAge 8Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
Sherr JL, Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Zgorski M, Tichy E, Tamborlane WV, Weinzimer SA. Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. Diabetes Care 2014, 37: 773-779. PMID: 24170766, PMCID: PMC3931387, DOI: 10.2337/dc13-1608.Peer-Reviewed Original ResearchConceptsBlood β-hydroxybutyrate levelsΒ-hydroxybutyrate levelsBasal insulinBlood glucose levelsBasal insulin infusionGlucose levelsBlood glucoseInsulin infusionMorning blood glucose levelsType 1 diabetic subjectsUsual basal ratesBasal rateLow glucose levelsSignificant ketonemiaDiabetic ketoacidosisDiabetic subjectsControl nightSensor-augmented pump systemGlucose valuesType 1Experimental nightInsulinLow glucoseNext morningInfusionReversal of Early Abnormalities in Glucose Metabolism in Obese Youth: Results of an Intensive Lifestyle Randomized Controlled Trial
Savoye M, Caprio S, Dziura J, Camp A, Germain G, Summers C, Li F, Shaw M, Nowicka P, Kursawe R, DePourcq F, Kim G, Tamborlane WV. Reversal of Early Abnormalities in Glucose Metabolism in Obese Youth: Results of an Intensive Lifestyle Randomized Controlled Trial. Diabetes Care 2014, 37: 317-324. PMID: 24062325, PMCID: PMC3898759, DOI: 10.2337/dc13-1571.Peer-Reviewed Original ResearchConceptsStandard of careClinical careBlood glucoseObese adolescentsObese youthOral glucose tolerance test glucoseIntensive lifestyle modificationDiabetes Prevention ProgramStandard clinical careInsulin sensitivity indexHealthy lifestyle programType 2 diabetesRisk of T2DChildhood obesity epidemicΒ-cell dysfunctionLifestyle modificationControlled TrialsOGTT glucosePrimary outcomeGlucose toleranceInsulin resistanceLifestyle programAnthropometric assessmentEarly abnormalitiesGlucose levels
2013
Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes
Sherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA. Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. Diabetes Care 2013, 36: 2909-2914. PMID: 23757427, PMCID: PMC3781513, DOI: 10.2337/dc13-0010.Peer-Reviewed Original ResearchConceptsNocturnal hypoglycemiaType 1 diabetesAfternoon exerciseInsulin deliveryAntecedent exerciseTarget blood glucose rangeCL insulin deliveryClosed-loop insulin deliveryLoop insulin deliveryTarget rangeBlood glucose levelsBlood glucose rangeMaximum heart rateCL controlBrisk treadmillReduced hypoglycemiaSedentary dayExercise dayPercentage of timeGlucose levelsHeart rateGlucose valuesType 1Random orderStudy period
2012
Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, . Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function. Diabetes Care 2012, 35: 817-820. PMID: 22323414, PMCID: PMC3308298, DOI: 10.2337/dc11-2190.Peer-Reviewed Original ResearchConceptsResidual β-cell functionΒ-cell functionSensor glucose levelsLower glucose variabilityType 1 diabetesGlucose levelsContinuous glucose monitoringT1D participantsGlucose variabilityMean sensor glucose levelPeak C-peptide levelsMixed meal tolerance testTarget A1C levelsC-peptide levelsLong-term T1DShort-term groupNondiabetic groupT1D groupA1c levelsT1D patientsLess hyperglycemiaNondiabetic individualsTolerance testInsulin treatmentHypoglycemia
2009
Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system.
Cengiz E, Swan KL, Tamborlane WV, Steil GM, Steffen AT, Weinzimer SA. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technology & Therapeutics 2009, 11: 207-10. PMID: 19344194, PMCID: PMC2842075, DOI: 10.1089/dia.2008.0102.Peer-Reviewed Original Research
2008
Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas
Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Diabetes Care 2008, 31: 934-939. PMID: 18252903, DOI: 10.2337/dc07-1967.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose levelsHCl groupFCL groupInsulin pumpBeta cell replacement therapyPostprandial glycemic excursionsPostprandial glucose excursionsPostprandial glucose levelsClosed-loop glucose controlArtificial pancreasClosed-loop artificial pancreasPediatric patientsPostprandial excursionsBolus dosesGlycemic excursionsReplacement therapySubcutaneous routeGlucose controlGlucose excursionsInsulin delivery systemsHybrid closed-loop controlInsulin absorptionType 1Dl
2007
Degree of Obesity and Glucose Allostasis Are Major Effectors of Glucose Tolerance Dynamics in Obese Youth
Weiss R, Cali AM, Dziura J, Burgert TS, Tamborlane WV, Caprio S. Degree of Obesity and Glucose Allostasis Are Major Effectors of Glucose Tolerance Dynamics in Obese Youth. Diabetes Care 2007, 30: 1845-1850. PMID: 17475938, DOI: 10.2337/dc07-0325.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testDegree of obesityElevated glucose levelsObese youthGlucose toleranceAmbient glycemiaInsulin sensitivityGlucose levelsSecond oral glucose tolerance testBaseline BMI z-scoreGlucose tolerance testBMI z-scoreAltered glucose metabolismCross-sectional analysisTolerance testInsulin sensitizationGlucose metabolismObesityZ-scoreLongitudinal assessmentLongitudinal changesMajor effectorGlycemiaSignificant reduction
2006
Effects of hypoglycemia on human brain activation measured with fMRI
Anderson AW, Heptulla RA, Driesen N, Flanagan D, Goldberg PA, Jones TW, Rife F, Sarofin H, Tamborlane W, Sherwin R, Gore JC. Effects of hypoglycemia on human brain activation measured with fMRI. Magnetic Resonance Imaging 2006, 24: 693-697. PMID: 16824963, DOI: 10.1016/j.mri.2006.03.013.Peer-Reviewed Original ResearchConceptsFunctional magnetic resonance imagingBrain activationHuman brain activationPassive sensory stimulationCognitive tasksFMRI activityVisual stimuliEuglycemic clamp studiesBlood glucose levelsLevel-dependent contrastEffects of hypoglycemiaBOLD signalSensory stimulationHealthy human subjectsVisual stimulationMagnetic resonance imagingHyperinsulinemic hypoglycemicHealthy brainAcute hypoglycemiaGlucose levelsClamp studiesResonance imagingFractional signal changeHypoglycemiaEuglycemia